This funding round was led by Bain Capital Life Sciences and SV Health Investors. They join existing investors, including Bill Gates and Access Biotechnology. The money will be used to support several clinical trials.
A couple of times over the past few years I tried to find if there was a Serbian restaurant in New York City, but Google could not find one. So, I gave up looking and assumed there wasn't one. And that was true - until recently.
"In my view you cannot claim to have seen something until you have photographed it.", Emile Zola (1840-1902)
Or, in modern online usage - "Pics, or it didn't happen!"
So, here are some of the pick from last night. First, we went to Seed offices, where we met everyone during the Happy Hour, including the Overlords, Erin and Arikia:
Posted on 394
Palleon Pharmaceuticals, a company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, today announced the appointment of Nikola Trbovic, Ph.D., Executive Director and Partner at Pfizer Ventures, as a member of its Board of Directors.
“Nikola’s expertise in R&D and corporate finance will be an asset to Palleon, and we are very pleased to welcome him to the Board. Nikola will replace Bill Burkoth, who we would like to thank for the valuable support and guidance that he has given to Palleon over the years,” said Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon. “This is an exciting time of growth for the company as our lead program, an enzymatic sialoglycan degrader for T cell exhaustion in cancer, is expected to enter clinical testing later this year. We look forward to working closely with Nikola as we advance our programs to first